<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01931748</url>
  </required_header>
  <id_info>
    <org_study_id>UNCNT3</org_study_id>
    <nct_id>NCT01931748</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome</brief_title>
  <acronym>UNCNT</acronym>
  <official_title>Study of Non-inferiority UNCNT Versus MELSMON in Female With Menopausal Syndrome: Randomized Confirmatory Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unimed Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unimed Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to evaluate in a randomized, double-blind, Parallel,&#xD;
      Non-inferiority, Multicenter, the efficacy and safety of UNCNT in comparison to the active&#xD;
      comparator of MELSMON in female having menopausal syndrome. Patients will be allocated&#xD;
      randomly to receive either UNCNT or MELSMON.&#xD;
&#xD;
      Through the injection of UNCNT to female having menopausal disorder, efficacy in the&#xD;
      improvement of the menopausal symptoms by Kupperman index is to be evaluated and compared&#xD;
      with MELSMON.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kupperman index score</measure>
    <time_frame>baseline and 12days</time_frame>
    <description>Mean difference of single clinical symptom in Kupperman index from baseline to 12days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>E2</measure>
    <time_frame>baseline and 12days</time_frame>
    <description>Change in blood serum of estradiol from baseline to 12days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSH (Folic Stimulating Hormone)</measure>
    <time_frame>baseline and 12days</time_frame>
    <description>Change in blood serum of Follicle-Stimulating Hormone from baseline to 12days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hot flushes</measure>
    <time_frame>baseline and 12days</time_frame>
    <description>Change in frequency and mean differences of hot flushes from baseline to 12days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Menopausal Syndrome</condition>
  <arm_group>
    <arm_group_label>UNCNT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 times/ 12 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MELSMON</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 times/ 12 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MELSMON</intervention_name>
    <arm_group_label>MELSMON</arm_group_label>
    <other_name>6 times/ 12 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UNCNT</intervention_name>
    <arm_group_label>UNCNT</arm_group_label>
    <other_name>6 times/ 12 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman ≥ 40 years old&#xD;
&#xD;
          -  Corresponding to one of the following criteria : Postmenopausal woman&#xD;
&#xD;
               1. spontaneous amenorrhea for 12 month&#xD;
&#xD;
               2. Blood serum of FSH concentration exceeds 40mlU/mL, spontaneous amenorrhea for&#xD;
                  6month&#xD;
&#xD;
               3. passed for at least 6 weeks of bilateral ovariectomy&#xD;
&#xD;
               4. History of bilateral hysterectomy pasted at least 6week and blood serum of FSH&#xD;
                  more than 40mLU/ml&#xD;
&#xD;
          -  Confirmed using a hot flashes recorded daily diary at visit 2: More 3-4 (times/ per&#xD;
             day) moderate or severe flush at least a day or occurrence of more than 20 times a&#xD;
             week to check flush&#xD;
&#xD;
          -  Kupperman Index Score ≥ 15 point&#xD;
&#xD;
          -  Serum Estradiol ≤ 30pg/mL&#xD;
&#xD;
          -  Able to communicate to conduct the clinical trial according to the protocol&#xD;
&#xD;
          -  Informed consent by oneself&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to drugs or any ingredient&#xD;
&#xD;
          -  Psychological menopausal disorder&#xD;
&#xD;
          -  History of carcinoma such as liver cancer etc&#xD;
&#xD;
          -  In the investigator's judgment, which will be unable to participate in this study&#xD;
&#xD;
               -  uncontrolled hypertensive(170/110mmHg more), severe disease (eg., of the&#xD;
                  cardiovascular, liver, kidney) or diabetic mellitus&#xD;
&#xD;
          -  History of hysterectomy or bilateral ovariectomy within 6 weeks&#xD;
&#xD;
          -  Patients whose blood serum AST/ALT, bilirubin and creatinine are more two times the&#xD;
             normal maximum rate.&#xD;
&#xD;
          -  Receiving hormone therapy such as estrogen, progestin or hormone of this class within&#xD;
             a month&#xD;
&#xD;
          -  Patients are participated in other clinical trials, and then receiving investigational&#xD;
             product within 3 months.&#xD;
&#xD;
          -  Usage of prohibit combination dug&#xD;
&#xD;
          -  history of alcohol and drug abuse&#xD;
&#xD;
          -  Washout requirement for hormone therapy such as estrogen or products involved like&#xD;
             estrogen/progestin component ( If who has washout period of following criteria, the&#xD;
             subject can participate in this study)&#xD;
&#xD;
               1. hormonal vaginal formulation (ring, cream, gels, etc) ≥ 1 weeks&#xD;
&#xD;
               2. estrogen single agent or estrogen/progestin-containing subcutaneous formulation ≥&#xD;
                  4 weeks&#xD;
&#xD;
               3. Oral estrogen or progestin therapy ≥ 8 weeks&#xD;
&#xD;
               4. Progestin intrauterine therapy ≥ 8 weeks&#xD;
&#xD;
               5. single injection of estrogen and progestin formulation transplant ≥3 month&#xD;
&#xD;
               6. injection of progestin or estrogen pellet method ≥ 6 month&#xD;
&#xD;
          -  In woman ≥40 age, known or suspicion of breast cancer at Breast angiographic and&#xD;
             normal pregnancy breast test within 9 month; history of breast cancer; Family history&#xD;
             of breast cancer in one generation&#xD;
&#xD;
          -  In Thickness of uterine intima ≥5mm as determined by TUVS, known or suspicion of&#xD;
             endometrial hyperplasia or endometrial cancer by performing the endometrial biopsy&#xD;
&#xD;
          -  known or suspicion of Cervical cancer in pap test ( pap smear)&#xD;
&#xD;
          -  otoscleorsis&#xD;
&#xD;
          -  Taking rifampicin induced liver microsome enzyme ( eg., Barbiturates, Hydantion,&#xD;
             carbamazepine, mepeu donkey mate, John diphenyl butadiene)&#xD;
&#xD;
          -  Jaundice, Dubin-Johnson syndrome or Rotor syndrome&#xD;
&#xD;
          -  Vaginal bleeding for unknown reason&#xD;
&#xD;
          -  Sickle cell anemia&#xD;
&#xD;
          -  Severe metabolic disorder (eg., porphyria..)&#xD;
&#xD;
          -  Thrombotic phlebitis, thrombosis, embolism patients, or those patients with a history&#xD;
&#xD;
          -  Cerebral, coronary altery disease&#xD;
&#xD;
          -  Thyroid disease, infectious disease&#xD;
&#xD;
          -  Experience of using placenta drug&#xD;
&#xD;
          -  Other circumstances that make the investigator expect an incomplete study&#xD;
             participation of the patient&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inha Univ.Hospital,</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Medical center Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

